raloxifene hydrochloride has been researched along with abaloparatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, DM; Cheung, AM; Eastell, R; Murad, MH; Rosen, CJ; Shoback, D | 1 |
| Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N | 1 |
1 review(s) available for raloxifene hydrochloride and abaloparatide
| Article | Year |
|---|---|
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting | 2021 |
1 other study(ies) available for raloxifene hydrochloride and abaloparatide
| Article | Year |
|---|---|
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Topics: Absorptiometry, Photon; Accidental Falls; Bone Density Conservation Agents; Calcitonin; Calcium; Clinical Decision-Making; Denosumab; Diphosphonates; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Patient Preference; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Teriparatide; Vitamin D | 2019 |